India Pharma Outlook Team | Wednesday, 23 September 2026
Regulatory radar lights up across Indian pharma manufacturing as Glenmark and Dishman secure clean or near-clean FDA outcomes while Piramal and Cohance receive Form-483 observations.
The mixed results offer a clear snapshot of compliance status for India’s CDMO and API export engine.
Glenmark’s Goa formulations plant earns a Voluntary Action Indicated status. Dishman’s Swiss subsidiary clears its first-ever USFDA inspection with zero observations.
Piramal’s UK facility and Cohance’s Andhra Pradesh API site each draw multiple observations.
These parallel developments place the sector under the microscope and highlight both strengths and areas that require corrective action. Companies now move to address findings or build on successful clearances.
Glenmark Pharmaceuticals receives the Establishment Inspection Report from the USFDA for its formulations manufacturing facility in Goa. The inspection runs from June 22 to June 30, 2026. The agency assigns a Voluntary Action Indicated status.
This outcome confirms a mild but passing result that allows the plant to continue operations while Glenmark undertakes any voluntary improvements.
Dishman Carbogen Amcis reports a stronger signal. A Swiss subsidiary, Carbogen Amcis, completes the first USFDA inspection at its Vionnaz manufacturing site with zero observations. The clean result delivers important regulatory validation while the parent company navigates a challenging financial year.
Key points from the successful inspections:
Piramal Pharma announces that its Morpeth facility in the UK undergoes a USFDA Good Manufacturing Practices audit. The inspection concludes with a Form-483 that lists seven observations. The company prepares a comprehensive response to address the findings.
Cohance Lifesciences discloses that its Jaggaiahpet, Andhra Pradesh-based API manufacturing facility receives a Form-483 with five observations. The USFDA inspects the site from September 14 to 19, 2026.
The company does not disclose the nature of the observations. Cohance initiates appropriate corrective and preventive actions and will submit its response within the required timeline.
Key points from the observation reports:
Glenmark and Dishman demonstrate that Indian-linked manufacturing sites can meet USFDA standards with minimal or no findings. Piramal and Cohance now focus on resolving the listed observations so that further regulatory action does not follow.
An observation under Form-483 signals conditions that may violate the Food, Drug, and Cosmetic Act or related rules. Companies treat these as early warnings and respond with corrective plans.
The current set of outcomes leaves India’s CDMO and API export base with a balanced compliance picture. Regulators and customers continue to watch the follow-up responses for confirmation that the sector continues to strengthen its manufacturing controls.
.jpg)
